<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04524195</url>
  </required_header>
  <id_info>
    <org_study_id>J19119</org_study_id>
    <secondary_id>IRB00208724</secondary_id>
    <nct_id>NCT04524195</nct_id>
  </id_info>
  <brief_title>PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Study of PET Imaging of T-cell Activation With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC) Patients Undergoing PD-1/PD-L1-directed Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CellSight Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stand Up To Cancer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single center, single-arm clinical trial in 20 patients with non-small&#xD;
      cell lung cancer (NSCLC) undergoing PD-1/PD-L1-directed therapy. This research is being done&#xD;
      to find out if the radioactive compound called [18F]F-AraG is a helpful imaging agent for&#xD;
      detecting changes in cancer's anti-tumor immune response (or activation of T-cell) levels for&#xD;
      non-small cell lung cancer (NSCLC) patients who will receive a cancer immunotherapy regimen&#xD;
      (immunotherapy works by encouraging the body's own immune system to attack the cancer cells).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to find out how the radiotracer called [18F]F-AraG can help&#xD;
      investigate changes in cancer's anti-tumor immune response (or activation of T-cell) levels&#xD;
      during positron emission tomography (PET) scans. [18F]F-AraG has the potential to serve as a&#xD;
      noninvasive imaging biomarker in the monitoring of T-cell mediated anti-tumor immune response&#xD;
      following administration of an immunotherapeutic agent.&#xD;
&#xD;
      Participants in this study will have tests, exams and procedures that are for study purposes.&#xD;
      Participants will be in this study up to one month which will include about three clinic&#xD;
      visits.&#xD;
&#xD;
      A baseline [18F]F-AraG PET-CT will be obtained 0-7 days before a NSCLC patient receives&#xD;
      PD-1/PD-L1 immunotherapy. A second [18F]F-AraG PET-CT will be performed 10-14 days after&#xD;
      PD-1/PD-L1 immunotherapy is administered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in uptake of [18F]F-AraG before and after one dose of anti-PD-L1</measure>
    <time_frame>Baseline and 10-14 days after first dose of neoadjuvant therapy</time_frame>
    <description>Percent Change in standard uptake value (SUV) of [18F]F-AraG PET-CT imaging of primary tumor and of lymph nodes at baseline to after the first dose of neoadjuvant therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent pathologic response at the time of surgery</measure>
    <time_frame>At the time of surgery</time_frame>
    <description>100% minus the percentage of viable tumor remaining in the tumor bed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between [18F]F-AraG uptake and percent pathologic response as assessed by the Spearman correlation coefficient</measure>
    <time_frame>5 years</time_frame>
    <description>Spearman correlation coefficient will be calculated in assessing the correlation between [18F]F-AraG uptake and pathologic response.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Non-small Cell Lung Cancer (NSCLC)</condition>
  <arm_group>
    <arm_group_label>[18F]F-AraG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A one-time nominal injection dose of 5 millicurie (mCi) +/- will be administered at each PET/CT imaging time point.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]F-AraG Injection</intervention_name>
    <description>Single dose of 5 mCi+/- [18F]F-AraG IV injection followed by the PET/CT scan. A baseline [18F]F-AraG PET/CT will be performed at about 0-7 days before patient receives the first dose of PD-1/PD-L1 immunotherapy. A second [18F]F-AraG PET-CT will be performed at less than 14 days after the first dose of PD-1/PD-L1 immunotherapy is administered and before the second dose of PD-1/PD-L1 immunotherapy is given.</description>
    <arm_group_label>[18F]F-AraG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older and willing and able to provide informed consent.&#xD;
&#xD;
          -  Subjects with stage I, II, or III A NSCLC and plan to receive neoadjuvant PD-1/PD-L1&#xD;
             immunotherapy with an intention for curative surgery. Subjects will be receiving&#xD;
             neoadjuvant immunotherapy through enrollment in therapeutic clinical trials&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 at the time&#xD;
             of enrollment.&#xD;
&#xD;
          -  For females of childbearing potential, negative serum pregnancy test within a 10 day&#xD;
             period will be obtained prior to PET study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe impaired renal function with estimated glomerular filtration rate &lt;30&#xD;
             mL/min/1.73 m2 and/or on dialysis.&#xD;
&#xD;
          -  Pregnant female patients; breastfeeding female patients.&#xD;
&#xD;
          -  Any medical condition that in the opinion of the study investigators would constitute&#xD;
             a safety risk to the subject.&#xD;
&#xD;
          -  Any investigational radiation exposure in the past calendar year that in combination&#xD;
             with the radiation exposure from this study would exceed 5 rem.&#xD;
&#xD;
          -  Administered a radioisotope â‰¤5 physical half-lives prior to the day of PET/CT.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Pomper, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary K Brosnan, BA</last_name>
    <phone>410-955-8264</phone>
    <email>mbrosna1@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rehab AbdAllah, MB BCH</last_name>
    <phone>410-955-6615</phone>
    <email>rabdall1@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary K Brosnan, BA</last_name>
      <phone>410-955-8264</phone>
      <email>mbrosna1@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rehab Abdallah, MB BCh</last_name>
      <phone>410-955-6615</phone>
      <email>rabdall1@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Pomper, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 19, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2020</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>J19119</keyword>
  <keyword>PET/CT</keyword>
  <keyword>[18F]F-AraG</keyword>
  <keyword>NSCLC</keyword>
  <keyword>PD-1</keyword>
  <keyword>PD-L1</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

